Log In
Print
BCIQ
Print
Print this Print this
 

KAE609 (formerly NITD609)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionSpiroindolone
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMalaria
Indication DetailsTreat malaria
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today